Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a

被引:52
作者
Bachelet, Ido [1 ]
Munitz, Ariel [1 ]
Berent-Maoz, Beata [1 ]
Mankuta, David [2 ]
Levi-Schaffer, Francesca [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel
关键词
D O I
10.4049/jimmunol.180.9.6064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Through its receptor Kit (CD117), stem cell factor (SCF) critically regulates human mast cell (MC) differentiation, survival, priming, and activation. The dominance of SCF in setting these parameters compels stringent contra-regulation to maintain a balanced MC phenotype. We have synthesized a library of bispecific Ab fragments to examine the effect of linking Kit with CD300a. In this study, we report that CD300a exerts a strong inhibitory effect on Kit-mediated SCF-induced signaling, consequently impairing MC differentiation, survival, and activation in vitro. This effect derives from Kit-mediated tyrosine phosphorylation of CD300a and recruitment of the SHIP-1 but not of SH2-containing protein phosphatase 1. CD300a inhibits the constitutive activation of the human leukemic HMC-1 cells but not their survival. Finally, CD300a abrogates the allergic reaction induced by SCF in a murine model of cutaneous anaphylaxis. Our findings highlight CD300a as a novel regulator of Kit in human MC and suggest roles for this receptor as a suppressor of Kit signaling in MC-related disorders.
引用
收藏
页码:6064 / 6069
页数:6
相关论文
共 34 条
[1]   The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast [J].
Bachelet, I ;
Munitz, A ;
Moretta, A ;
Moretta, L ;
Levi-Schaffer, F .
JOURNAL OF IMMUNOLOGY, 2005, 175 (12) :7989-7995
[2]  
BACHELET I, J ALLERGY CLIN IMMUN, V117, P1314
[3]   PREPARATION OF BISPECIFIC ANTIBODIES BY CHEMICAL RECOMBINATION OF MONOCLONAL IMMUNOGLOBULIN-G1 FRAGMENTS [J].
BRENNAN, M ;
DAVISON, PF ;
PAULUS, H .
SCIENCE, 1985, 229 (4708) :81-83
[4]  
Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO
[5]  
2-L
[6]  
DVORAK AM, 1994, AM J PATHOL, V144, P160
[7]   gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo [J].
Feldweg, AM ;
Friend, DS ;
Zhou, JS ;
Kanaoka, Y ;
Daheshia, M ;
Li, L ;
Austen, KF ;
Katz, HR .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (08) :2262-2268
[8]   IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT [J].
FURITSU, T ;
TSUJIMURA, T ;
TONO, T ;
IKEDA, H ;
KITAYAMA, H ;
KOSHIMIZU, U ;
SUGAHARA, H ;
BUTTERFIELD, JH ;
ASHMAN, LK ;
KANAYAMA, Y ;
MATSUZAWA, Y ;
KITAMURA, Y ;
KANAKURA, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1736-1744
[9]   Mast cells as "tunable" effector and immunoregulatory cells: Recent advances [J].
Galli, SJ ;
Kalesnikoff, J ;
Grimbaldeston, MA ;
Piliponsky, AM ;
Williams, CMM ;
Tsai, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :749-786
[10]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580